Anti-RFWD2 monoclonal antibody

Pre-made anti-RFWD2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to RFWD2/COP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T12819-Ab-1/ GM-Tg-hg-T12819-Ab-2Anti-Human RFWD2/COP1 monoclonal antibodyHuman
GM-Tg-rg-T12819-Ab-1/ GM-Tg-rg-T12819-Ab-2Anti-Rat RFWD2/COP1 monoclonal antibodyRat
GM-Tg-mg-T12819-Ab-1/ GM-Tg-mg-T12819-Ab-2Anti-Mouse RFWD2/COP1 monoclonal antibodyMouse
GM-Tg-cynog-T12819-Ab-1/ GM-Tg-cynog-T12819-Ab-2Anti-Cynomolgus/ Rhesus macaque RFWD2/COP1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T12819-Ab-1/ GM-Tg-felg-T12819-Ab-2Anti-Feline RFWD2/COP1 monoclonal antibodyFeline
GM-Tg-cang-T12819-Ab-1/ GM-Tg-cang-T12819-Ab-2Anti-Canine RFWD2/COP1 monoclonal antibodyCanine
GM-Tg-bovg-T12819-Ab-1/ GM-Tg-bovg-T12819-Ab-2Anti-Bovine RFWD2/COP1 monoclonal antibodyBovine
GM-Tg-equg-T12819-Ab-1/ GM-Tg-equg-T12819-Ab-2Anti-Equine RFWD2/COP1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T12819-Ab-1/ GM-Tg-hg-T12819-Ab-2; GM-Tg-rg-T12819-Ab-1/ GM-Tg-rg-T12819-Ab-2;
GM-Tg-mg-T12819-Ab-1/ GM-Tg-mg-T12819-Ab-2; GM-Tg-cynog-T12819-Ab-1/ GM-Tg-cynog-T12819-Ab-2;
GM-Tg-felg-T12819-Ab-1/ GM-Tg-felg-T12819-Ab-2; GM-Tg-cang-T12819-Ab-1/ GM-Tg-cang-T12819-Ab-2;
GM-Tg-bovg-T12819-Ab-1/ GM-Tg-bovg-T12819-Ab-2; GM-Tg-equg-T12819-Ab-1/ GM-Tg-equg-T12819-Ab-2
Products NameAnti-RFWD2/COP1 monoclonal antibody
Formatmab
Target NameRFWD2
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-RFWD2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T12819-Ag-1Recombinant multi-species COP1/ RFWD2/ RNF200 protein


    Target information

    Target IDGM-T12819
    Target NameRFWD2
    Gene ID64326,26374,360860,708802,480060,101098108,519896,100061855
    Gene Symbol and SynonymsCFAP78,COP1,FAP78,RFWD2,RGD1304773,RNF200
    Uniprot AccessionQ8NHY2
    Uniprot Entry NameCOP1_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000143207
    Target ClassificationN/A

    The target: RFWD2, gene name: COP1, also named as RFWD2, RNF200. Enables ubiquitin protein ligase activity. Involved in positive regulation of proteasomal ubiquitin-dependent protein catabolic process; proteasome-mediated ubiquitin-dependent protein catabolic process; and response to ionizing radiation. Part of Cul4A-RING E3 ubiquitin ligase complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.